

Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.
You can purchase shares of Vistagen Therapeutics (NASDAQ:VTGN) through any online brokerage.
Other companies in Vistagen Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Vistagen Therapeutics has a consensus price target of $6.45.
The stock price for Vistagen Therapeutics (NASDAQ: VTGN) is $0.1788 last updated October 23, 2026 at 7:18 PM EDT.
There are no upcoming dividends for Vistagen Therapeutics.
Vistagen Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Vistagen Therapeutics.
Vistagen Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue,...